The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation-Reference-Cited by-同舟云学术

The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody-Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation

Published:2010-12-27 Issue:12 Volume:90 Page:1486-1492
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Flechner Stuart M.,Fatica Richard,Askar Medhat,Stephany Brian R.,Poggio Emilio,Koo Anna,Banning Stacey,Chiesa-Vottero Andres,Srinivas Titte

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference18 articles.

1. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial.;Terasaki;Transplantation,2005

2. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation.;Hourmant;J Am Soc Nephrol,2005

3. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis.;Colvin;J Am Soc Nephrol,2007

4. The effect of desensitization protocols on human splenic B-cell populations in vivo.;Ramos;Am J Transplant,2007

5. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG.;Perry;Am J Transplant,2008

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune reactions following intestinal transplantation: Mechanisms and prevention;Asian Journal of Surgery;2024-09

2. Current Therapies in Kidney Transplant Rejection;Journal of Clinical Medicine;2023-07-27

3. Curbing proteastasis to combat antibody-mediated rejection post lung transplant;Indian Journal of Transplantation;2023

4. Innovations in Immunosuppression for Intestinal Transplantation;Frontiers in Nutrition;2022-06-15

5. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials;Expert Opinion on Emerging Drugs;2022-04-03